{
  "nctrialId": "HC-1266",
  "title": "A  Double-Blind, Active-Controlled Multi-Center Study of SMA-668 (SMN2 splicing modifier) in Patients With Osteoporosis",
  "officialTitle": "A  Double-Blind, Active-Controlled Multi-Center Study of SMA-668 (SMN2 splicing modifier) in Patients With Osteoporosis",
  "sponsor": "University of Alberta",
  "indication": "Osteoporosis",
  "phase": "Phase 3",
  "fileName": "HC-1266.json",
  "fileSize": 310116,
  "date": "2023-09-26",
  "completionDate": "2026-12-22",
  "drugName": "SMA-668 (SMN2 splicing modifier)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Not yet recruiting",
  "description": "This is a  double-blind, active-controlled multi-center study designed to evaluate the efficacy and safety of SMA-668 (SMN2 splicing modifier) in patients with Osteoporosis. The study will enroll approximately 510 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 20-57 years\n- Confirmed diagnosis of Osteoporosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}